{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:30Z","timestamp":1760060190275,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BiologicsMD"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Alopecia areata (AA) is an autoimmune disorder of hair loss resulting from a T-cell mediated attack on hair follicles. Three Janus kinase (JAK) inhibitors have been approved for the treatment of moderate-to-severe alopecia areata; however, safety concerns for immunosuppressive therapy have limited their use. We previously demonstrated that BMD-1141, consisting of parathyroid hormone (PTH) fused to a collagen-binding domain (CBD) (PTH-CBD) improved hair retention, increased anagen hair follicles counts, and reduced hair follicle dystrophy in C3H\/HeJ-engrafted mice). We now compare the effects of a single subcutaneous injection of BMD-1141 with the daily, high-dose, oral administration of the JAK inhibitor ruxolitinib on anagen hair follicle counts and hair regrowth in C3H\/HeJ-engrafted mice. BMD-1141-treated mice exhibited a significant increase in anagen hair follicle counts (p &lt; 0.05) and enhanced hair regrowth compared to ruxolitinib-treated mice after 8 weeks. Hair follicles from the BMD-1141-treated mice showed increased beta-catenin, consistent with a mechanism of stimulating the anagen transition of hair follicles, and did not increase immune cell infiltration. Thus, a single subcutaneous dose of BMD-1141 stimulated hair regrowth comparable to daily ruxolitinib, apparently by stimulating the hair cycle, rather than inhibiting the autoimmune response.<\/jats:p>","DOI":"10.3390\/cells14161251","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T14:51:46Z","timestamp":1755183106000},"page":"1251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata"],"prefix":"10.3390","volume":"14","author":[{"given":"Robert","family":"Gensure","sequence":"first","affiliation":[{"name":"Dartmouth Health Children\u2019s, Lebanon, NH 03766, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[{"name":"Independent Researcher, Fairfield, CT 06430, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-530X","authenticated-orcid":false,"given":"Stephen","family":"Sikkink","sequence":"additional","affiliation":[{"name":"School of Chemistry and Biosciences, University of Bradford, Manchester BD7 1DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Mardaryev","sequence":"additional","affiliation":[{"name":"Revenue Jersey, St. Helier, Jersey JE4 8PF, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Goforth","sequence":"additional","affiliation":[{"name":"BiologicsMD, New Haven, CT 06511, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: What\u2019s new in the epidemiology, comorbidities, and pathogenesis?","volume":"112","author":"Dainichi","year":"2023","journal-title":"J. Dermatol. Sc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","article-title":"Comorbidities in alopecia areata: A systematic review and meta-analysis","volume":"80","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s40257-023-00808-1","article-title":"Alopecia Areata: Current Treatments and New Directions","volume":"24","author":"Dahabreh","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Van Acker, M.M., Schwartz, R.R., Andrews, K., Seiffert-Sinha, K., and Sinha, A.A. (2023). Inheritance-Specific Dysregulation of Th1-and Th17-Associated Cytokines in Alopecia Areata. Biomolecules, 13.","DOI":"10.3390\/biom13091285"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"955035","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"30","author":"Lensing","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.0022-202X.2005.23787.x","article-title":"A guide to assessing damage response pathways of the hair follicle: Lessons from cyclophosphamide-induced alopecia in mice","volume":"125","author":"Hendrix","year":"2005","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: An Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the Treatment of Alopecia Areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/1523-1747.ep12468979","article-title":"Cyclosporin A prolongs human hair growth in vitro","volume":"100","author":"Taylor","year":"1993","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9554.10000307","article-title":"Treatment of Alopecia Areata in Mice by Stimulating the Hair Follicles Using Parathyroid Hormone Agonists Linked to a Collagen Binding Domain","volume":"6","author":"Katikaneni","year":"2015","journal-title":"J. Clin. Exp. Dermatol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","article-title":"Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts","volume":"111","author":"McElwee","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jps.23843","article-title":"Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct","volume":"103","author":"Stratford","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2013.07.015","article-title":"Treating osteoporosis by targeting parathyroid hormone to bone","volume":"19","author":"Ponnapakkam","year":"2014","journal-title":"Drug Discov. Today"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/16\/1251\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:12Z","timestamp":1760034432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/16\/1251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":18,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cells14161251"],"URL":"https:\/\/doi.org\/10.3390\/cells14161251","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}